Endometrial ablation is the removal or destruction of the lining of the womb. It is an alternative to hysterectomy for many women with heavy periods (menorrhagia) who wish to avoid major gynaecological surgery. It is generally performed as a day-case procedure and most women return to normal daily activities within a couple of days. Increased vaginal discharge for 2-4 weeks is normal as the lining of the womb is shedding. Intercourse and strenuous activities should be avoided for about 2 weeks. Patient selection and surgeon experience are essential elements to a successful outcome of endometrial ablation.
Endometrial ablation can be performed using a special hysteroscope (telescope) called a resectoscope. This instrument allows visualisation of the cavity of the womb and has a built-in wire loop or roller-ball that uses high-frequency electrical energy to cut or coagulate tissue. The procedure is carried out under anaesthesia. Approximately 85% of women experience relief of their symptoms within the first few months, with many having scant or absent periods after the procedure. Other methods of ablation have more recently been introduced. The Thermachoice™ balloon uses a balloon filled with hot water which is placed in the uterine cavity through the cervix. The Microwave Endometrial Ablation (MEA) involves inserting a microwave probe (long slender tube) into the cavity of the womb to heat the lining. With the temperature maintained at 75-80˚C, the probe is moved from side to side of the uterine cavity to destroy the tissue.
The risks of endometrial ablation procedures include perforation of the womb, infection, bleeding, excess fluid absorption, injury to pelvic and abdominal organs.
Since endometrial ablation will destroy the lining of the womb, which is essential for embryo implantation and establishment of pregnancy, ablation of the endometrium should not be offered to women who wish to maintain their fertility. It also should not be performed on women with pre-malignant or malignant conditions of the womb, and in women with active pelvic inflammatory disease (PID).